FDA approves new cell therapy manufacturing plant
European Pharmaceutical Review
JUNE 11, 2023
The US Food and Drug Administration (FDA) has approved commercial production at Bristol Myers Squibb’s newest cell therapy manufacturing facility in Devens, Massachusetts. The site is a “critical component” of BMS’ expanding global cell therapy manufacturing footprint, the company said. “The
Let's personalize your content